Figure 2

Verapamil protects MIN6 cells against diabetogenic stressors STZ and T1D-cytomix. To detect the protective role of verapamil in MIN6 cells challenged with diabetogenic stressors, MTT assay was conducted on the cells cultured in a high-glucose medium in the presence or absence of stressors (STZ or T1D-cytokine cocktail with different timing of different doses of verapamil (1, 5, 10, and 50 μM) for 24 h under pre-, post-, or co-treatment conditions. (A,B) Verapamil pre-treatment condition for 24 h, then challenging with STZ or TD-cytomix stressors, respectively. Pre-treatment with verapamil significantly improved cell survival dose-dependently. (C,D) Verapamil post-treatment enhanced cell recovery moderately after challenge with STZ (C) but significantly improved cell survival post-T1D-cytomix cocktail (D) treatments for 24 h. (E,F) Verapamil and stressor co-treatment for 24 h showed significant protection against STZ (E) and T1D-cytomix (F). Data is presented as the ratio of cell viability of verapamil-treated cells to verapamil-untreated cells. All experiments included >5 biological replicates. Data are presented as mean ± SEM and were analyzed by two-way analysis of variance (ANOVA), and p < 0.05 was considered a significant difference. ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: non-significant.